Tema Oncology ETF (NASDAQ:CANC – Get Free Report) was the recipient of a significant decrease in short interest during the month of August. As of August 14th, there was short interest totaling 10,698 shares, a decrease of 47.3% from the July 30th total of 20,291 shares. Currently, 0.2% of the shares of the company are sold short. Based on an average daily trading volume, of 17,651 shares, the short-interest ratio is currently 0.6 days.
Tema Oncology ETF Price Performance
NASDAQ:CANC traded down $0.49 during midday trading on Monday, hitting $43.03. The company’s stock had a trading volume of 10,035 shares, compared to its average volume of 31,533. Tema Oncology ETF has a fifty-two week low of $26.52 and a fifty-two week high of $47.00. The firm has a market cap of $205.25 million, a P/E ratio of 20.39 and a beta of 0.68. The firm’s 50 day moving average is $41.87 and its 200-day moving average is $38.86.
Hedge Funds Weigh In On Tema Oncology ETF
A number of institutional investors have recently modified their holdings of the stock. Thrivent Financial for Lutherans raised its position in Tema Oncology ETF by 891.1% during the fourth quarter. Thrivent Financial for Lutherans now owns 1,461,649 shares of the company’s stock valued at $50,747,000 after acquiring an additional 1,314,177 shares in the last quarter. Jane Street Group LLC purchased a new stake in Tema Oncology ETF during the fourth quarter worth $1,100,000. Flow Traders U.S. LLC acquired a new stake in Tema Oncology ETF during the third quarter valued at $630,000. Roxbury Financial LLC grew its position in Tema Oncology ETF by 326.4% during the second quarter. Roxbury Financial LLC now owns 3,940 shares of the company’s stock valued at $162,000 after buying an additional 3,016 shares during the period. Finally, LPL Financial LLC purchased a new position in Tema Oncology ETF in the fourth quarter valued at $278,000.
Tema Oncology ETF Company Profile
The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.
Recommended Stories
- Five stocks we like better than Tema Oncology ETF
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
- AST SpaceMobile Is Down 54%—Can FCC Progress and BlueBirds Reverse the Slide?
- Don’t Miss These 3 Companies Delivering Strong Guidance Updates
Receive News & Ratings for Tema Oncology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tema Oncology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
